gala glp 1 reviews consumer reports GLP-1 Review: Program Details & Feedback GLP-1 CPG Consumer Trends |

Using any unlicensed injectable compound carries inherent and serious risks

D., Wadden, T

meal-kit market was ~$10.4B in 2023 and is growing ~1011% CAGR through 2030

J., Orskov, C., Ritzel, R., & Schmiegel, W

2,3 The REDEFINE 1 trial found that when evaluating the treatment effect regardless of whether patients stayed on treatment, those treated with CagriSema achieved weight loss of 20.4% (from an average baseline body weight of 236 lb.) at 68 weeks versus 3.0% (from an average baseline body weight of 235 lb.) for the placebo group which was statistically significant

For people who want to avoid injections, there are even more options now: In late 2025, the U.S